Make the purchase path trustworthy
- Optimise live WGS + heart campaigns
- Launch claims-gated BRCA Search in W2
- Expand testing to other platforms
- Website Renovate DTC answer and checkout route
- Start SEO foundations and neutral review requests
Grow WGS,
one buyer journey at a time.
A 26-week acquisition and answer-network plan built around one commercial score: reconciled net WGS purchase revenue ÷ paid-media spend.
Executive decision
Optimise the campaigns already running, renovate the direct purchase journey, and test YouTube plus LinkedIn in Week 3. Treat WorkMagic as a Month-2 feasibility pilot—not a substitute for first-party measurement.
26
operating weeks
evidence-gated, not calendar-scaled
SEM vs SEO
Two keyword clusters have been tackled. There are 98 more. We have barely begun chipping at the iceberg.
SEO vs SEM ROI (3-year average)
Source: FirstPageSage. SEO compounds; SEM stays linear.
The iceberg principle. What is live today — two keyword clusters in Google Ads — is the visible tip. Below the waterline sit 98 more clusters across cancer genomics, hereditary risk, preventive screening, test comparison, assay choice, BRCA, pharmacogenomics and family planning. Each cluster is a buyer journey waiting to be built. The plan chips methodically: Month 1 adds BRCA; Month 2 expands condition and comparison groups; Month 3 scales what purchase evidence supports.
Competitor teardowns
Competitor: Nucleus
Nucleus is the fastest-growing consumer-WGS brand, and it runs almost no paid digital acquisition — but that is a deliberate model, not a gap. It manufactures demand through outrage-bait PR and a NYC out-of-home blitz, then converts the earned attention with a templated organic + AI-search engine. The lesson for HLI is a demand-creation playbook, and the trust white-space that Nucleus’s controversy leaves wide open.
Founded 2021 by Thiel Fellow Kian Sadeghi; ~$32M raised (Founders Fund, Alexis Ohanian’s Seven Seven Six, Samsung Next; angels incl. Balaji Srinivasan). NY-based DTC genomics. Scope note: the $499 consumer WGS is the top of a reproductive-genetics funnel — the real revenue sits in IVF (below).
~$0
Paid digital adsZero Google, Meta & TikTok — confirmed in each ad-transparency library. But paid marketing overall is not zero (see below).
8,400
Organic keywordsvs HLI’s 290. Nucleus owns the WGS category in search.
238
AI-search citationsChatGPT (58), Google AI Overviews (69), AI Mode (60) & Gemini (51).
$31K
Monthly organic valueSearch traffic they earn free each month instead of buying.
1,700%
Claimed sales liftSelf-reported by the founder after the Nov-2025 subway blitz — unverified, but the direction is the point.
0
Medical reviewersNo author byline or medical reviewer on their content — an authority gap HLI can exploit.
What they actually spend on — it isn’t nothing
The “~$0 paid” reading only covers the trackable digital channels Semrush and the ad libraries measure. Nucleus’s real marketing money goes into channels those tools can’t see — which is exactly why it looked like zero.
Out-of-home blitz (the big spend)
A full-station takeover of Broadway–Lafayette plus 1,000+ subway-car and street ads across NYC (Nov 2025), rerun in 2026 with IVF physicians added for credibility. Copy — “IQ is 50% genetic,” “Height is 80% genetic,” “Have your best baby” — drove to pickyourbaby.com. The MTA rejected some creative. A large, real cash outlay that no digital-ad tracker records.
Stunts, influencers & earned media
Reported logo placement at a Jake Paul PPV bout (unconfirmed); free genomes seeded to influencers for reviews; and a deliberate outrage-bait engine that earned WSJ, Fast Company, MIT Tech Review, CBS, Ad Age and a Tucker Carlson segment. The strategy is “paid media as a PR trigger,” not paid media as a direct-response funnel.
Why there’s no paid search or social — healthcare restriction, by design. Genetic-testing and health claims are heavily restricted on the ad platforms: Google’s personalized-genetic-testing / health policies and Meta’s health & genetics rules block most of the targeting and creative a normal DTC brand would use — you effectively cannot run compliant performance ads for “choose your baby’s traits.” On top of policy, there’s live regulatory scrutiny: BBB National Programs’ National Advertising Division recommended Nucleus modify or discontinue certain IVF+ embryo-screening claims (Nucleus is appealing). Buying ads against contested claims invites disapproval and legal exposure — so Nucleus creates demand through earned media and OOH instead. The zero isn’t weakness; it’s the only channel mix the category allows.
The WGS acquisition engine
Once the PR manufactures attention, three non-paid engines convert it: brand-driven Direct traffic, comparison + educational SEO worth ~$31K/mo, and a strong AI-search (GEO) citation footprint.
1 · Comparison-conquest SEO
30+ “X vs Y” and 25+ “[brand] review” posts intercepting competitor search — 23andMe, Natera, Quest, LabCorp, Promethease, Genetic Genie, Viome. A templated content system, not editorial (a live unrendered [PRICE] token gives it away). Every post ends in the same “Order your kit” pitch + “you may also like” internal-link module.
2 · GEO / AI-search
Snippet-shaped H2s, comparison tables and definitional blocks engineered for LLM extraction — but with no medical reviewer. They win on structure, not authority.
3 · Educational demand capture
“What is ___” genetics content (carrier screening, fetal fraction, sequencing, disease-risk) that owns top-of-funnel WGS curiosity and feeds the brand. Plus a longevity/biohacking halo (Bryan Johnson, NAD, Oura) for reach.
Product & revenue ladder — WGS is the loss-leader
The $499 consumer genome is the cheap top of an IVF upsell ladder. That reframes Nucleus: it isn’t really competing with HLI on WGS economics — WGS is customer-acquisition for a reproductive business.
| Tier | Price | What it is |
|---|---|---|
| Nucleus Health | ~$499 one-time (+~$39/yr) | Consumer 30x WGS, “2,000+ conditions” — the funnel entry |
| Nucleus Preview | Couple (price uncertain) | Preconception two-person test incl. non-disease traits |
| Nucleus Embryo | $9,999 | Polygenic embryo ranking for IVF (up to 20 embryos) |
| Nucleus IVF+ | ~$9,999/mo ×4 (~$40K) | Full IVF concierge: clinic matching, cycle, counseling |
The keyword gap — HLI vs Nucleus (WGS terms)
HLI ranks for 290 organic keywords; Nucleus for 8,400. HLI holds its own brand but has ceded the WGS category.
| WGS / genetic-testing keyword | HLI position | Nucleus position | Volume |
|---|---|---|---|
| whole genome sequencing companies | 41 | 11 | 140 |
| whole genome sequencing providers | 49 | 13 | 50 |
| personal whole genome sequencing | 41 | 31 | 50 |
| sequencing HLI ranks 0 | — | 35 | 14,800 |
| carrier screening HLI ranks 0 | — | 36 | 2,900 |
| fetal fraction HLI ranks 0 | — | 1 | 3,600 |
The pattern: among consumer-genomics disruptors, paid search is run by nobody — Nucleus, like Nebula, spends ~$0 on trackable ads because the category won’t let them. Their moat is manufactured attention → organic + GEO capture. HLI is currently absent from both.
What HLI should take from this
- Don’t try to out-SEM Nucleus — they are not there, and the same health-ad restrictions apply to HLI. Compete on the organic and GEO lanes, and on OOH/PR where HLI’s clinical story actually lands.
- Copy the GEO template, then out-trust it. Same structured, table-heavy answer pages — but with named MDs/PhDs and primary literature Nucleus lacks.
- Weaponize the controversy. Nucleus is publicly tied to “eugenics” framing, a Theranos comparison and an NAD claims ruling. HLI’s clean, physician-grade, disease-risk-only position is the trust white-space — lead with it.
- Build the comparison-conquest library — “HLI vs Nucleus”, “WGS vs 23andMe” — and reclaim the WGS category terms HLI ranks 0 for.
Sources: Semrush (US, 14 Sep 2026); Google Ads Transparency Center, Meta & TikTok Ad Libraries (verified 16 Sep 2026); mynucleus.com; WSJ, Fast Company, MIT Tech Review, TechCrunch, Ad Age, BBB National Programs / NAD. Scope: consumer WGS + funnel; embryo/IVF included for revenue context. Some prices marked approximate/uncertain in source research.
Competitor: Natera
Natera is not a consumer-WGS brand — it’s the clinical-diagnostics incumbent (NIPT, oncology MRD, carrier screening) and the one rival running real paid search. It matters to HLI as the auction HLI bids into and the GEO benchmark to beat.
189K
Organic visits/mo~13× the DTC players; 19K organic keywords.
310
Paid keywordsThe genomics PPC whale — 15.2K paid visits/mo, ~400 live Google ads.
1,100
AI-search citations~5× the DTC players — clinical authority dominates AI Overviews (485).
$2.9B
2026 revenuePublic (NTRA), +38% YoY, SG&A >$1B/yr — well-capitalized for sustained spend.
Zenith
New WGS assayJust launched a clinician-facing WGS test — watch for a DTC move.
0
Medical reviewersSame GEO gap: strong FAQ schema & citations, but no named-reviewer byline.
Product lines & funnel
| Product | What it does | Buyer / billing |
|---|---|---|
| Panorama | NIPT (prenatal screening) | Clinician-ordered, insurance-billed |
| Signatera | ctDNA cancer-recurrence (MRD) monitoring | Clinician + biopharma |
| Horizon | Carrier screening | Clinician-ordered |
| Prospera | Transplant-rejection testing | Clinician-ordered |
| Zenith new | Whole-genome assay (rare disease) | Clinician-facing (not consumer yet) |
No consumer buy-button anywhere — the funnel is clinician-ordered and insurance-billed. A class action over billing opacity (advertised ~$249 vs. real bills into the thousands) is unresolved.
What their ads actually say: ~400 Google ads (condition-specific Signatera for breast, head & neck, lung; plus Panorama) and Meta patient-testimonial + clinician-technical campaigns. Every ad pushes clinician-ordered testing — none message direct-to-consumer self-ordering. That is exactly HLI’s $599, no-prescription position, and it is uncontested ad-copy space.
What HLI should take from this
- Don’t outbid Natera head-on on generic terms (“dna test”, “genetic testing”). Target WGS-specific and consumer long-tail instead.
- Own the uncontested DTC message. Natera’s ads all say “only a healthcare provider can order” — HLI’s no-prescription self-order is clear white space.
- Copy the evidence-forward pattern (outcome headline + hard proof point + soft CTA) and the cluster + FAQ-schema architecture — then add the named medical reviewers Natera omits.
- Make the flat $599 cash price a trust asset against Natera’s billing-opacity litigation.
- Watch Zenith. If Natera takes WGS direct-to-consumer, the white space narrows.
Sources: Semrush (US, 14 Sep 2026); Google Ads Transparency Center & Meta Ad Library (verified 16 Sep 2026); natera.com; Natera Q2 2026 results.
Competitor: Nebula
Nebula is the closest head-to-head WGS product to HLI — and a distressed, for-sale asset in wind-down. The near-term opportunity is to capture its displaced customers and its SEO equity before an acquirer does.
~0
Paid adsMeta confirmed zero; ~46 Google ads on file but stale (last seen Nov 2025).
12,500
Organic keywordsLegacy content, largely frozen since the 2025 rebrand — ripe to take.
237
AI-search citationsStrong AI Overview presence (126) on the old content.
$595
WGS price (30x)Near HLI parity up front — but a $195/yr renewal on top (subscription).
Feb 2025
Brand shut downConsumer Nebula closed; relaunched as “DNA Complete” under ProPhase.
For sale
Wind-downThinkEquity shopping it; headcount 96→28, sequencing lab closed.
Head-to-head: HLI vs Nebula (30x WGS)
| HLI | Nebula “DNA Complete” Pro | |
|---|---|---|
| Depth | 30x WGS | 30x WGS |
| Up-front price | $599 (flat) | $595 (sale; $895 list) |
| Recurring fee | None | $195/yr renewal, auto-renews |
| 3-year cost | ~$599 | ~$985 |
| Reports | — | 250+ (350+ only on the $1,295 Elite tier) |
Acquisition & weaknesses
How they acquire
Branded SEO + Direct (~45%), an Awin affiliate network feeding coupon sites, ~41 influencer sponsorships (led by an ex-Barstool exec), review-site placement (DNA Weekly, Innerbody), and 23andMe/Ancestry raw-data upload interception. Lean, mostly outsourced — no viral PR, minimal paid.
Where they’re weak
Chronic fulfillment complaints (Trustpilot: 4+ month delays, refund refusals), an unresolved Illinois genetic-privacy class action (data-sharing with Meta/Google), and a frozen content library since the rebrand. A shrinking, distracted competitor.
The real risk isn’t Nebula — it’s who buys it. Nebula is pitched on its 16-petabyte genomic dataset + SEO equity + affiliate relationships. A well-capitalized acquirer inheriting those is the threat; the shrinking current operation is an opportunity.
What HLI should take from this
- Publish a migration guide — “Nebula shut down? Move your genome to HLI” — to catch displaced customers now.
- Attack the subscription trap: HLI’s flat $599 vs Nebula’s $595 + $195/yr forever (~$985 over 3 years).
- Clone the low-CAC channel mix (affiliate + influencer + review-site + raw-data upload interception) — the pattern is proven and cheap.
- Exploit the fulfillment gap — message reliable turnaround against Nebula’s delivery reputation.
- Contest the “100% vs <1% of DNA” AI-Overview soundbite with HLI’s own crisp, numeric, table-ready claim plus named medical reviewers.
Sources: Semrush (US, 14 Sep 2026); Google Ads Transparency Center & Meta Ad Library (verified 16 Sep 2026); nebula.org / dnacomplete.com Terms of Use; ProPhase Labs disclosures. Prices approximate/sale-dependent.
Competitor: Function Health
Function isn’t a genome company — it’s the membership that owns the “test everything about me” mindset HLI wants. It sells 100+ blood biomarkers on a yearly subscription, not DNA, so it competes with HLI for the same proactive-longevity customer and the same “most comprehensive test” search intent, from an adjacent lane.
$365/yr
Membership modelRecurring; cut from the $499 launch price. 160+ lab tests/yr (100+ markers at the annual draw + a 60+ follow-up) — a subscription, vs HLI’s one-time genome.
Blood, not DNA
Different testBiomarker panels (metabolic, hormones, heart, toxins), not sequencing. Complementary to WGS, not a substitute — a co-positioning angle for HLI.
Podcast/KOL
Acquisition engineCo-founded with Dr. Mark Hyman; grows on podcast/influencer reach (Huberman-sphere) + waitlist virality, not search ads. a16z-backed; acquired Ezra (full-body MRI).
Why it matters to HLI: Function has trained an affluent audience to pay a yearly fee to “see inside” their health — and owns the term (“function health review,” 3,600/mo). HLI’s genome answers the one question Function’s bloodwork can’t (inherited risk). The play is a “DNA + biomarkers” complement narrative and a “Function Health vs whole-genome” comparison page, not a head-on fight. Figures approximate; valuation/raise per press, treat as directional.
Competitor: Grail / Galleri
Grail’s Galleri is the premium “detect cancer early from one blood draw” test — a multi-cancer early-detection (MCED) screen, not inherited-risk sequencing. It matters to HLI as the other high-priced, high-intent proactive-health product competing for the same affluent buyer, and as the one adjacent player that does run real DTC advertising.
~$949
Galleri MCED testcfDNA-methylation blood test screening 50+ cancer types; prescription required, largely out-of-pocket.
Runs paid
Unlike the WGS setGrail advertises (TV + digital) — the exception that proves the rule: cancer-screening ad copy clears policy where “genetic optimization” does not.
GRAL
Independent againSpun from Illumina; the Illumina acquisition was unwound under FTC/EU antitrust — Grail now trades on its own.
Why it matters to HLI: Galleri owns the “galleri test” / “galleri test cost” search (~8,100/mo) and the mental model of paying ~$1K for early detection — a price anchor that makes HLI’s $599 whole genome look modest. Different test (cancer signal now vs inherited risk for life), so the angle is “WGS vs Galleri: what each actually finds,” positioning HLI as the lifetime-risk complement to Galleri’s point-in-time cancer screen.
90-day roadmap
Add bounded evidence layers
- Continue CRO, creative and Search tests
- Run AI Ad buys W5–8 in parallel
- Build comparison A/B Landing pages
- Maintain channel-level purchase ROAS
Scale what purchase evidence supports
- Increment supported PPC spend
- Scale clinically reviewed SEO/GEO editorial
- Strengthen reviews and decision support
- Measure marginal and blended ROAS separately
Scale is earned, not scheduled. The $1M/month all-paid-media aspiration is not a Month-3 commitment or proof of absorbable demand. Assess Search capacity separately.
Week-by-week
W01Optimise current WGS + heart
Snapshot live settings; clean off-offer queries; separate promises; repair routes and purchase measurement. Deliver change sheets, BRCA brief and two scripts.
W02BRCA1/BRCA2
Claims-gated Search and one combined WGS decision page; clarify germline/tumor testing, result states, price, limits and clinical handoff.
W03Improve YouTube + pilot LinkedIn
Optimise the existing contextual/KOL activity and run a separately budgeted LinkedIn consumer-video pilot; reconcile purchases by channel.
W04Pharmacogenomics: DNA and medication response
Prepare and run a narrow general PGx testing/price group where approved; validate candidate phrases such as `pharmacogenetic test` and `dna test for medication`. Review Week 3 placements and hooks separately · Medication-report explanation, supported medication list and limits; one PGx script. HLI publicly lists a medication report, but do not promise a specific drug recommendation or infer CYP2D6/CYP2C19 coverage
W05WGS versus 23andMe / existing DNA tests
Add a controlled comparison-intent group; keep upload/login/support and ancestry-only intent out of the WGS purchase group · Comparison page explaining what different assays/returned reports provide, what remains useful in an old test, and when buying WGS may not be necessary. One comparison video cut
W06Lynch syndrome and inherited colorectal-cancer questions
Complete a named keyword packet: `lynch syndrome genetic testing`, testing cost and hereditary-colorectal testing language. Activate only if HLI confirms the actual report/variant scope and clinical pathway · Clinically reviewed inherited-colorectal/Lynch explanation and scope answer. The public offer does not explicitly confirm Lynch; internal factsheet wording alone does not authorise a purchase promise
W07Familial hypercholesterolemia / inherited high cholesterol
Refine the existing heart campaign with verified inherited-risk testing intent; separate lipid blood-test and scan purchasers. Test the FH-specific group only if product scope is confirmed · FH/family-history education and a comparison of germline information with lipid measurements. LDLR/APOB/PCSK9 inclusion is not publicly confirmed; do not present this as a delivered gene panel
W08HLI versus Nebula/DNA Complete, tellmeGen and Nucleus
Validate and isolate consumer review/comparison queries; inspect actual competitor ads and landing pages relevant to these terms · One maintained comparison resource covering current US price/renewal, assay, reports, process and limits. Avoid three thin template pages; a competitor's visible ads do not prove its ROAS
W09What is in the WGS report?
Test report-preview/inclusions messaging in the existing WGS ads and landing page, holding other variables stable · Approved sample-report walkthrough, annotation of actual returned fields, limitations and physician-discussion guidance; video walkthrough adapted to both channels
W10DNA privacy, access and data ownership
Test a substantiated trust-message variation within existing WGS acquisition; do not buy raw-upload service intent without an actual service · Reconciled privacy/access FAQ with retention, deletion, sharing, raw-file availability and support answers. State unresolved terms plainly rather than inventing “your data stays yours” promises
W11BRCA family-history questions, including men
Extend the Week 2 query packet only where consumer intent and approved report scope support it; otherwise use the questions to improve the BRCA page · BRCA family-history/men FAQ and second BRCA video concept; no implication that a negative result removes the need for screening or clinical evaluation
W12$599 offer-page conversion test
Run one controlled test of price-first versus verified-inclusions-first presentation; review Search/YouTube/LinkedIn purchase cohorts · Two versions of the existing offer presentation—not two competing indexed pages. Record real orders/revenue and checkout friction; do not infer a winning version from clicks alone
W13Search versus YouTube versus LinkedIn
Reconciled channel/cohort scorecard, attribution gaps, duplicate-order check and next test allocations. Assess each channel separately before blending
W14PGx report interpretation; CYP2D6/CYP2C19 verification
Named drug–gene scope checklist and a medication-results FAQ; add gene-specific groups only for validated included reports
W15Lynch/colorectal result meanings and next steps
Positive/negative/uncertain-result FAQ and clinical-handoff module, or a clear product-exclusion statement if the Week 6 verification did not support the offer
W16Inherited heart risk versus cholesterol tests and calcium scans
Correct the specific confusion present in the original campaign; improve the comparison module, exclusions and cardiac-genomics ad copy without claiming WGS replaces imaging or blood tests
W17Heart-video second creative round
Two new openings using the best-supported Week 3/7/16 message; retain comparable landing routes and independent YouTube/LinkedIn reporting
W18BRCA-video second creative round
Clinically approved explanation of what the actual BRCA assessment can and cannot answer, with matching BRCA page and purchase route
W19WGS versus exome versus genotyping
One assay-choice resource and a bounded comparison-query test; avoid treating technical curiosity as proven purchase intent
W20Provider comparison refresh
Recheck Nebula/DNA Complete, tellmeGen and Nucleus US offers/ads; update the Week 8 resource and retire outdated claims or keywords
W21At-home kit, sample return and turnaround
Process FAQ/video and a landing-page variant addressing verified order-to-result expectations, failed-sample handling and support
W22SEO connections across WGS, BRCA, PGx and heart
Crawl/indexation/canonical review for built pages, remove duplicate intent, improve specific internal links and refresh titles/snippets from actual search queries
W23One approved offer test
A single owner-approved offer against the current $599 control, with consistent eligibility/terms and actual discounted revenue in ROAS. If no offer is approved or volume is insufficient, test a non-price objection instead
W24Search spend-capacity test
Controlled incremental spend test on supported existing groups; report actual delivery, overlap, purchase maturity and marginal revenue—not summed keyword-volume TAM
W25YouTube/LinkedIn scale and attribution sensitivity
Separate channel spend tests where supported; compare click-linked and platform-reported outcomes without adding duplicate credit; document unmeasured view-through effects
W26Six-month outcome and next-quarter build queue
Updated keyword/page workbook, tested versus untested topics, reconciled purchase ROAS, remaining research gaps and the next named weekly packages
Live entities to verify:
04 · repair before expansionTrustini | DNA + Heart | Sales and Trustini | Sales | Genomics. The Jan–Sep audit is a dated baseline, not a fresh account read.Existing ads & DTC
WGS campaign
Separate genuine WGS purchase intent from MRI, biomarker and other-service traffic. Preserve useful comparison questions.
Heart campaign
Separate inherited-risk messaging from calcium scans and lipid blood tests. Verify the live route and geography.
Purchase path
Align ad promise → answer page → $599 offer → checkout. Reconcile real orders, discounts and mature refunds.
DTC release acceptance
Price, reports, scope, limitations, sample-report preview, saliva process, verified turnaround, privacy facts and mobile checkout must be findable. Accept when ad/page promises match, checkout works, one real order records once, and claims/data handling are reviewed.
Page interactions diagnose friction. Only paid WGS product purchases count as the commercial conversion.
Video & audience
YouTube is already live. Week 3 improves current health/KOL activity, while LinkedIn is a new, separately measured pilot. Begin with two contextual clusters selected from the live placement report—not every possible matrix cell.
What WGS returns
Truthful general WGS explainer. 30–45s master plus 15–30s cut; 16:9 YouTube and 4:5 LinkedIn adaptations.
WGS route$599 qualifierFamily history + heart
Genetics may be one part of an inherited-risk answer. No promise that WGS replaces imaging, blood tests or clinical evaluation.
Heart answer routeClaims review| Channel | Targeting approach | Business score |
|---|---|---|
| YouTube | US contextual placements/topics; no purchaser, visitor or health-risk lookalikes by default | Reconciled purchase ROAS |
| US consumer video pilot; seniority is a hypothesis, not purchase intent; no hospital procurement | Reconciled purchase ROAS, not leads or views |
Policy boundary: contextual placement is not a lookalike. Do not use purchaser, visitor or video-engager lists for sensitive-health personalization by default. Keep genetic findings, conditions and health-bearing URLs out of ad payloads.
Weeks 5–8: fit demonstration → approved read-only feed → parallel reconciliation → accept useful modules, defer unsupported ones, or retain the simpler ledger.
06 · measurement layerScale & measurement
Adopt now
First-party order truth, UTMs, paid SKU, net merchandise revenue, refunds and separate media spend.
Pilot in Month 2
Read-only, side-by-side feasibility check after custom checkout, Stripe, LinkedIn and YouTube ingestion are verified.
Defer
Causal MMM and incrementality until history, volume and data quality support them. No automatic platform actions.
Vendor-stated fit: approximately 3,000+ monthly orders is a best-fit indication for incrementality testing—not an MTA eligibility rule.
Foundations now; editorial scale later. Month 1 establishes crawlability, product facts, review ownership and neutral customer feedback. Month 3 expands clinically reviewed answers and separately observes AI citations.
07 · connected answersSEO, GEO & reviews
SEO foundation · Month 1
Resolve page purpose, route quality, canonical questions, internal links and structured answers during DTC renovation.
GEO editorial · Month 3
Publish extractable, cited answers for WGS, reports, comparisons, conditions, limits and next steps.
Reviews · start Month 1
Invite authentic existing-customer feedback through a compliant process. Do not manufacture Reddit advocacy.
Topical map (v3)
Full Koray-method topical map for consumer WGS: one central entity → 9 topical pillars → ~253 topics grounded in real Semrush US volumes. Colour = zone: Core (money/decision) · Outer (bridged breadth) · Border (excluded). Bubble size = full phrase-cluster search volume/mo (KMT). Toggle HLI coverage view to see content gaps (red). Drag to arrange, click any node for full data (bridge, clinical limit, HLI coverage, keywords), scroll to zoom, go full screen. Add / edit / remove nodes; changes autosave in your browser.
AllCoreOuterBorder
$1M / month breakdown
Monthly media and content investment at scale. 90% on paid acquisition through Google Ads, 10% on organic authority and community presence.
SEM · $900,000 / month
Google Ads across 100 keyword clusters. Scale is earned: spend increases only where reconciled purchase evidence supports it.
100
keyword clusters identified
2
clusters live today
$599
WGS target product
1,500
target orders / month at scale
SEO & Others · $100,000 / month
Organic authority, community presence and answer-engine visibility.
- SEO content & technical$45K
- Wikipedia editing$15K
- Reddit community$15K
- GEO / AI answer visibility$15K
- Review & reputation$10K
DNA testing universe
Full phrase-match keyword clusters per segment (every keyword containing the seed phrase), not just head terms — Semrush US Keyword Magic, 2026-09-17. Segments are largely distinct and exclude brand-navigational terms and the broad long-tail. The reframing holds even at full scale: whole-genome sequencing is ~1% of the DNA-testing universe.
~1,970,510DNA-testing segment demand / mo (full clusters)
18,680WGS core (0.95% of DNA segments)
7.76M“dna test” broad umbrella (all long-tail)
Ancestry & genealogyborder · seed: ancestry dna
39.2%
+ brand nav: 23andme 301K, myheritage 8.1K, ancestry(brand) 1.5M
Paternity / relationshipborder (excluded) · seed: paternity test
16.0%
screens the father; off-strategy for HLI
Pet DNA (dog + cat)border · seed: dog dna + cat dna
13.3%
+ brand nav: embark 90.5K, wisdom panel 40.5K -> ~394K
Hereditary / clinical genetic testingHLI core · seed: genetic testing
13.3%
cancer, carrier, prenatal clinical intent
NIPT / prenatal screeningborder · seed: nipt
8.3%
screens the fetus, during pregnancy
DTC consumer test kitsadjacent-core · seed: dna test kit
5.5%
at-home kit demand (some ancestry/paternity overlap)
Aging / biological age / epigeneticadjacent (longevity) · seed: biological age
1.8%
HLI's positioning-adjacent
Whole genome sequencing (WGS)HLI CORE · seed: whole genome sequencing
0.9%
HLI's core product cluster
Carrier / reproductive (before pregnancy)HLI outer · seed: carrier screening
0.6%
screens the parents, preconception
Cancer early detection (ctDNA)adjacent · seed: galleri
0.6%
Galleri/GRAIL cluster
PharmacogenomicsHLI outer · seed: pharmacogenomic
0.2%
drug-response genetics
Traits & wellnessHLI outer · seed: dna diet
0.1%
+ nutrigenomics 1.9K
Strategic implication (unchanged, now on firmer numbers). Even counting full clusters (~1,970,510/mo of DNA-testing demand), WGS is ~1%. Ancestry (772K), paternity (315K), pet (263K) and clinical genetic-testing (262K) dominate. HLI wins by intercepting adjacent high-volume clusters — clinical/hereditary genetic-testing intent, DTC kits, aging/biological-age, and the 1.8M+ biomarker-education pond — and routing health-intent to WGS as the deeper, one-time, lifelong-genome option. Paternity, pet and pure-ancestry stay border: captured for disambiguation, never sold as HLI coverage.
Broad umbrellas (overlap the segments)
“dna test” all-match: 7,756,350/mo · “genetic testing” all-match: 7,569,970/mo. These include long-tail across every segment — the true total DNA-search demand sits here, ~7.7M/mo.Brand navigational (not in clusters, add on top)
ancestry 1.5M · 23andme 301K · embark 90.5K · wisdom panel 40.5K. Real demand, but brand-specific — ancestry & pet grow further once brands are added.Adjacency — blood-biomarker / lab-result education (NON-DNA)
The “creatinine” cluster alone is 1.84M/mo — and that is one marker. This is the top-of-funnel pond sequencing.com and Function Health farm with lab-result explainers (Pillar J on the map). Enormous reach, no genomics required to enter it.Method. Semrush Keyword Magic Tool, Phrase Match (all keywords containing the exact seed phrase), US, 2026-09-17. Segments are phrase clusters and are largely distinct; they EXCLUDE brand-navigational terms and the broad long-tail captured by the 'dna test'/'genetic testing' umbrellas (~7.7M each). Biomarker adjacency shown for one marker (creatinine) only and is non-DNA.
WGS content backlog
The 70 map topics HLI’s short-read WGS can honestly deliver (the green “WGS-detectable” nodes), ranked as a build queue: demand (full phrase-cluster volume) × intent × HLI gap. Filter by tier; click Cluster/mo or # to sort. MTHFR leads on volume but is low-clinical-value top-of-funnel; BRCA & Lynch are the E-E-A-T anchors.
| # | Page | Target keyword | Cluster/mo | HLI | Page type | Tier |
|---|---|---|---|---|---|---|
| 1 | MTHFR Gene Variant | mthfr test | 361,450 | partial | Condition / risk explainer | P1 |
| 2 | Lynch Syndrome (Hereditary Colorectal & Endometrial Cancer) | lynch syndrome test | 94,580 | gap | Condition / risk explainer | P1 |
| 3 | BRCA1/BRCA2 (Hereditary Breast & Ovarian Cancer) | brca test | 101,190 | partial | Condition / risk explainer | P1 |
| 4 | Rare Blood Types — Rh-null & Bombay Phenotype Genetics | bombay group blood group | 26,210 | gap | Trait explainer | P1 |
| 5 | Brachydactyly & Rare Skeletal Trait Genetics | brachydactyly type d | 23,180 | gap | Trait explainer | P1 |
| 6 | Rare & Novelty Trait Genetics | Rare & Novelty Trait Genetics | 21,780 | gap | Trait explainer | P1 |
| 7 | Vitamin & nutrient metabolism genetics (B12, vitamin D, folate/MTHFR) | mthfr test | 26,730 | partial | Trait explainer | P1 |
| 8 | APOE & Alzheimer's Disease Risk | apoe test | 23,930 | partial | Condition / risk explainer | P1 |
| 9 | Color Vision & Deuteranomaly Genetics | deuteranomaly | 14,520 | gap | Trait explainer | P1 |
| 10 | Reproductive Carrier Screening | carrier screening test | 12,790 | partial | Condition / risk explainer | P1 |
| 11 | Expanded Carrier Screening Panel | expanded carrier screening | 12,790 | partial | Condition / risk explainer | P1 |
| 12 | Red Hair & MC1R Gene Genetics | hair dna test | 5,860 | gap | Trait explainer | P1 |
| 13 | Pharmacogenomics (Drug Response) | pharmacogenomic testing | 4,010 | partial | Condition / risk explainer | P1 |
| 14 | Factor V Leiden & Thrombophilia | factor v leiden test | 2,904 | partial | Condition / risk explainer | P1 |
| 15 | Ehlers-Danlos Syndrome (EDS) | ehlers danlos genetic testing | 1,947 | gap | Condition / risk explainer | P1 |
| 16 | Hereditary Cancer Risk | hereditary cancer test | 1,947 | partial | Condition / risk explainer | P2 |
| 17 | Common Polygenic Disease Risk (PRS) | polygenic risk score test | 1,947 | partial | Condition / risk explainer | P2 |
| 18 | Psychiatric & Pain Medication Response (CYP2D6/CYP2C19) | cyp2d6 test | 1,287 | gap | Condition / risk explainer | P2 |
| 19 | Hereditary Kidney & Connective Tissue Disorders | genetic testing for kidney disease | 1,287 | gap | Condition / risk explainer | P2 |
| 20 | Taste perception genetics (bitter taste, cilantro) | cilantro tastes like soap gene | 1,287 | no | Trait explainer | P2 |
| 21 | Cardiovascular Genetic Risk | heart disease genetic test | 1,584 | partial | Condition / risk explainer | P2 |
| 22 | Hereditary Hemochromatosis (HFE) | hemochromatosis genetic test | 1,584 | partial | Condition / risk explainer | P2 |
| 23 | Marfan Syndrome | marfan syndrome genetic test | 1,056 | gap | Condition / risk explainer | P2 |
| 24 | Sickle Cell Trait & Disease | sickle cell trait test | 1,287 | partial | Condition / risk explainer | P2 |
| 25 | Preconception Genetic Carrier Testing | preconception genetic testing | 1,287 | partial | Condition / risk explainer | P2 |
| 26 | Alpha-1 Antitrypsin Deficiency | alpha 1 antitrypsin deficiency test | 693 | gap | Condition / risk explainer | P2 |
| 27 | Food sensitivities & intolerance genetics (lactose, gluten) | lactose intolerance genetic test | 693 | gap | Trait explainer | P2 |
| 28 | Familial Hypercholesterolemia (FH) | familial hypercholesterolemia test | 693 | partial | Condition / risk explainer | P2 |
| 29 | Neurodegenerative Disease Risk | genetic test for alzheimer's | 693 | partial | Condition / risk explainer | P2 |
| 30 | Nutrigenomics & DNA diet | dna diet test | 561 | partial | Trait explainer | P2 |
| 31 | Cystic Fibrosis Carrier Status | cystic fibrosis carrier test | 363 | partial | Condition / risk explainer | P2 |
| 32 | Tay-Sachs Disease Carrier Status | tay sachs carrier test | 363 | partial | Condition / risk explainer | P2 |
| 33 | Atrial Fibrillation Genetic Risk | atrial fibrillation genetic risk | 231 | gap | Condition / risk explainer | P2 |
| 34 | Polycystic Kidney Disease (PKD) | polycystic kidney disease genetic testing | 231 | gap | Condition / risk explainer | P2 |
| 35 | Sensory & Musculoskeletal Hereditary Conditions | genetic testing for hearing loss | 231 | gap | Condition / risk explainer | P2 |
| 36 | Hereditary Hearing Loss | genetic testing for hearing loss | 231 | gap | Condition / risk explainer | P2 |
| 37 | Inherited Eye Disease Risk (AMD, Retinitis Pigmentosa) | macular degeneration genetic test | 231 | gap | Condition / risk explainer | P2 |
| 38 | Celiac Disease Genetic Risk (HLA-DQ2/DQ8) | celiac disease genetic test | 297 | partial | Condition / risk explainer | P2 |
| 39 | Muscle type & power vs endurance (ACTN3) | actn3 test | 132 | gap | Trait explainer | P2 |
| 40 | Caffeine metabolism genetics | caffeine metabolism test | 99 | gap | Trait explainer | P2 |
| 41 | Hair loss / baldness genetics (androgenetic alopecia) | baldness gene test | 99 | gap | Trait explainer | P3 |
| 42 | Metabolic & Liver Genetic Conditions | metabolic genetic testing | 99 | partial | Condition / risk explainer | P3 |
| 43 | Autoimmune Genetic Risk | autoimmune disease genetic testing | 99 | partial | Condition / risk explainer | P3 |
| 44 | Parkinson's Disease Genetic Risk | parkinson's genetic test | 66 | gap | Condition / risk explainer | P3 |
| 45 | Prostate Cancer Polygenic Risk Score | prostate cancer genetic risk score | 66 | gap | Condition / risk explainer | P3 |
| 46 | Alcohol metabolism genetics (ALDH2 flush) | aldh2 gene test | 66 | gap | Trait explainer | P3 |
| 47 | Nicotine metabolism genetics | nicotine metabolism gene test | 66 | gap | Trait explainer | P3 |
| 48 | Sleep chronotype & circadian genetics | chronotype genetic test | 66 | gap | Trait explainer | P3 |
| 49 | Common Single-Gene Variants & Carrier Conditions | genetic carrier test | 66 | partial | Condition / risk explainer | P3 |
| 50 | Thalassemia Carrier Status | thalassemia carrier test | 66 | partial | Condition / risk explainer | P3 |
| 51 | Hypertrophic Cardiomyopathy (HCM) & Cardiomyopathy Genes | hypertrophic cardiomyopathy genetic test | 33 | gap | Condition / risk explainer | P3 |
| 52 | Type 1 Diabetes Genetic Risk | type 1 diabetes genetic risk | 33 | gap | Condition / risk explainer | P3 |
| 53 | APOL1-Related Kidney Disease Risk | apol1 gene test | 33 | gap | Condition / risk explainer | P3 |
| 54 | Skin aging & collagen genetics | dna skin test | 33 | gap | Trait explainer | P3 |
| 55 | Fitness & athletic genetics | dna test for athletic performance | 33 | partial | Trait explainer | P3 |
| 56 | Hereditary Cancer Gene Panel (Multi-Gene: PALB2, ATM, CHEK2, TP53) | multi gene cancer panel test | 0 | gap | Condition / risk explainer | P3 |
| 57 | Long QT Syndrome & Inherited Arrhythmia Risk | long qt syndrome genetic test | 0 | gap | Condition / risk explainer | P3 |
| 58 | Hereditary Thoracic Aortic Aneurysm Risk | aortic aneurysm genetic test | 0 | gap | Condition / risk explainer | P3 |
| 59 | Wilson Disease | wilson disease genetic test | 0 | gap | Condition / risk explainer | P3 |
| 60 | Monogenic & Syndromic Obesity Risk | obesity gene test | 0 | gap | Condition / risk explainer | P3 |
| 61 | Cardiovascular & Clotting Drug Response (Warfarin, Clopidogrel, Statins) | warfarin genetic test | 0 | gap | Condition / risk explainer | P3 |
| 62 | Coronary Artery Disease Polygenic Risk Score | coronary artery disease genetic risk score | 0 | gap | Condition / risk explainer | P3 |
| 63 | Type 2 Diabetes Polygenic Risk Score | type 2 diabetes genetic risk test | 0 | partial | Condition / risk explainer | P3 |
| 64 | Breast Cancer Polygenic Risk Score | breast cancer polygenic risk score | 0 | gap | Condition / risk explainer | P3 |
| 65 | G6PD Deficiency | g6pd test | 0 | partial | Condition / risk explainer | P3 |
| 66 | Malignant Hyperthermia Genetic Risk | malignant hyperthermia genetic test | 0 | gap | Condition / risk explainer | P3 |
| 67 | Hereditary Muscular Dystrophy Carrier Status | muscular dystrophy carrier test | 0 | gap | Condition / risk explainer | P3 |
| 68 | Injury risk & recovery genetics | genetic testing for injury risk | 0 | gap | Trait explainer | P3 |
| 69 | VO2 max, trainability & recovery genetics | vo2 max genetic test | 0 | gap | Trait explainer | P3 |
| 70 | Weight, metabolism & appetite genetics | fto gene weight loss | 0 | partial | Trait explainer | P3 |
Command center
The chief of staff for this program. Talk to it on the right — “plan the BRCA cluster for October”, “we lost the PPC budget, reshuffle” — and it plans straight onto the board: cards, owners, two-week sprints, tasks with a medical-review gate, and a decision log. Every row in the backlog, every roadmap item and every competitor takeaway has a + board button that drops it here.